NCT06740474 is a Phase 1 clinical trial of ABI-6250 in Hepatitis Delta Virus, sponsored by Assembly Biosciences.

Who is sponsoring NCT06740474?

NCT06740474 is sponsored by Assembly Biosciences.

What drugs are being tested in NCT06740474?

Interventions in NCT06740474: ABI-6250, Placebo.

What condition does NCT06740474 study?

NCT06740474 studies Hepatitis Delta Virus, Hepatitis D.

Is NCT06740474 still recruiting?

NCT06740474 is currently completed. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT06740474

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

Completed Phase 1 Last updated 4 December 2025

What this trial tests

Phase 1 trial testing ABI-6250 in Hepatitis Delta Virus in 40 participants. Completed in 8 July 2025.

Timeline

31 January 2025

Primary endpoint
8 July 2025

8 July 2025

Quick facts

Lead sponsor	Assembly Biosciences
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	31 January 2025
Primary completion	8 July 2025
Estimated completion	8 July 2025
Sites	1 location across New Zealand

Drugs / interventions tested

ABI-6250 — full drug profile →
Placebo

Conditions studied

Hepatitis Delta Virus — all drugs for Hepatitis Delta Virus →
Hepatitis D — all drugs for Hepatitis D →

Sponsor

Assembly Biosciences — full company profile →

Who can join

Adults 18 to 60, any sex, with Hepatitis Delta Virus or Hepatitis D. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to assess safety, tolerability, and pharmacokinetics of single ascending doses (SAD) and multiple-ascending doses (MAD) of ABI-6250 in healthy participants. Effect of food will also be evaluated in Part A.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assembly Biosciences trials

Trials by the same sponsor.

NCT06698575 — A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropos · Phase 1 · completed
NCT06384131 — A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B · Phase 1 · completed
NCT06385327 — A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participa · Phase 1 · completed
NCT05569941 — A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects · Phase 1 · completed
NCT05414981 — A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06740474 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assembly Biosciences
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing